These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32671374)

  • 1. Design, organocatalytic synthesis, and bioactivity evaluation of enantiopure fluorinated LpxC inhibitors.
    Rodríguez-Alvarado M; Russo R; Connell ND; Brenner-Moyer SE
    Org Biomol Chem; 2020 Aug; 18(30):5867-5878. PubMed ID: 32671374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
    Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
    Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
    Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
    J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
    Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies.
    Dreger A; Hoff K; Agoglitta O; Hotop SK; Brönstrup M; Heisig P; Kirchmair J; Holl R
    Bioorg Chem; 2021 Feb; 107():104603. PubMed ID: 33429229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.
    Kline T; Andersen NH; Harwood EA; Bowman J; Malanda A; Endsley S; Erwin AL; Doyle M; Fong S; Harris AL; Mendelsohn B; Mdluli K; Raetz CR; Stover CK; Witte PR; Yabannavar A; Zhu S
    J Med Chem; 2002 Jul; 45(14):3112-29. PubMed ID: 12086497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold.
    Liang X; Lee CJ; Chen X; Chung HS; Zeng D; Raetz CR; Li Y; Zhou P; Toone EJ
    Bioorg Med Chem; 2011 Jan; 19(2):852-60. PubMed ID: 21194954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
    Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
    J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
    Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
    Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
    Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
    Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
    Müller H; Gabrielli V; Agoglitta O; Holl R
    Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
    Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
    Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa.
    Caughlan RE; Jones AK; Delucia AM; Woods AL; Xie L; Ma B; Barnes SW; Walker JR; Sprague ER; Yang X; Dean CR
    Antimicrob Agents Chemother; 2012 Jan; 56(1):17-27. PubMed ID: 22024823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.